Locus Biosciences

Locus Biosciences is a private, clinical-stage biotech leveraging a sophisticated AI and robotics platform, LOCUS, to industrialize the development of engineered bacteriophage therapies. The company's most advanced asset, LBP-EC01 for E. coli infections, has reported positive Phase 2 results, positioning it as a leader in the precision antibacterial space. Backed by significant NIH funding and strategic partnerships, Locus is expanding its pipeline to address antibiotic-resistant infections across multiple therapeutic areas while operating its own cGMP manufacturing facility.

LOCUS platform: An integrated AI, robotics, and synthetic biology platform for industrializing the development of engineered bacteriophage therapies. It combines a massive automated biobank, pangenomics with NLP-inspired models, and a cloud AI core to design precision phage cocktails with enhanced payloads.

Locus competes in the emerging phage therapy space with companies like Armata Pharmaceuticals, Adaptive Phage Therapeutics, and PhageTech, as well as with developers of other novel antimicrobials (e.g., lysins, narrow-spectrum antibiotics). Its key differentiator is the industrialized, AI-driven LOCUS platform for engineering phages with enhanced payloads, coupled with in-house cGMP manufacturing.